Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
The combination produced an overall response rate of 99%, and the 5-year remission rate was 76%.
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
All patients with cardiotoxicity recovered within 2 months.
A single-center study sought to determine the effects of SARS-CoV-2 vaccination in patients with myeloproliferative neoplasms.
Male survivors of classical Hodgkin lymphoma had lower childbearing rates if they received BEACOPP rather than ABVD.
